Open-label Randomized Multicenter Comparative Study on the Efficacy and Safety of AREPLIVIR® (Favipiravir) for Parenteral Administration (PROMOMED RUS LLC, Russia) in Hospitalized Patients With COVID-19
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 217
- 试验地点
- 6
- 主要终点
- Rate of Clinical Status Improvement
研究概览
简要总结
This is open-labe randomized multicenter comparative Phase III study conducted in 7 medical facilities. The objective of the study is to assess the efficacy and safety of Favipiravir for parenteral administration compared with the Standard of care (SOC) in hospitalized patients with moderate COVID-19 pneumonia.
详细描述
Upon signing the informed consent form and screening, 217 eligible patients hospitalized with COVID-19 pneumonia were randomized at a 1:1 ratio to receive either Favipiravir intravenously by drip infusion for 2 hours 1600 mg twice a day (BID) on Day 1 followed by 800 mg BID on Days 2-14 (1600/800 mg), or SOC. The course of treatment by Favipiravir is 10 days.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Availability of the Informed Consent Form of the Patient Information Leaflet (PIL) signed and dated by patient.
- •Men and women aged 18 to 80 years inclusive at the time of signing the Informed Consent Form in PIL.
- •Confirmed case of COVID-19 at the time of screening based on SARS-CoV-2 RNA test using nucleic acid amplification (NAA) method. It is acceptable to include a patient with a presumptive COVID-19 diagnosis prior to receiving the results of SARS-CoV-2 RNA test made at the screening stage.
- •Hospital admission due to COVID-
- •Moderate severity infection with SARS-CoV-2:
- •Clinical signs:
- •Mandatory: CT pattern typical of a viral lesion (lesion volume is minimal or moderate; CT 1-2).
- •Additional (at least 1 of the following criteria):
- •body temperature > 38 °C;
- •RR > 22/min;
- •shortness of breath on exertion;
- •SpO2 < 95%;
- •Serum CRP > 10 mg/L.
- •Patient's consent to use reliable contraceptive methods throughout the study and within 1 month for women and 3 months for men after its completion. Reliable means of contraception are: sexual abstinence, use of condom in combination with spermicide.
- •For men (optional): Consent to avoid sexual contact with pregnant women for the duration of the study and for 3 months after its completion.
- •Women incapable of childbearing may also participate in the study (with past history of: hysterectomy, tubal ligation, infertility, menopause for more than 2 years), as well as men with infertility or a history of vasectomy.
排除标准
- •Hypersensitivity to favipiravir, remdesivir and/or other components of the study drug.
- •Impossibility of CT procedure (for example, gypsum dressing or metal structures in the field of imaging).
- •History of vaccination against COVID-
- •History of presumptive or confirmed COVID-19 case of moderate, severe and extremely severe course of the disease.
- •Use of favipiravir or remdesivir within 10 days prior to screening.
- •The need to use drugs from the list of prohibited therapy.
- •Meeting the criteria for severe and extremely severe course of the disease.
- •Need for treatment in the intensive care unit.
- •Impaired liver function (AST and/or ALT ≥ 2 UNL and/or total bilirubin ≥ 1.5 UNL) at the time of screening.
- •Renal impairment (GFR < 60 ml/min) at the time of screening.
- •History of gout.
- •Positive testing for HIV, syphilis, hepatitis B and/or C.
- •Chronic heart failure FC III-IV according to New York Heart Association (NYHA) functional classification (see Appendix 2).
- •Malignancies in the past medical history.
- •Alcohol, pharmacological and/or drug addiction in the past medical history and/or at the time of screening.
- •Schizophrenia, schizoaffective disorder, bipolar disorder, or other history of mental pathology or suspicion of their presence at the time of screening.
- •Severe, decompensated or unstable somatic diseases (any disease or condition that threaten the patient's life or impair the patient's prognosis, and also make it impossible for him/her to participate in the clinical study).
- •Any history data that the investigating physician believes could lead to complication in the interpretation of the study results or create an additional risk to the patient as a result of his/her participation in the study.
- •Patient's unwillingness or inability to comply with procedures of the Study Protocol (in the opinion of physician investigator).
- •Pregnant or nursing women or women planning pregnancy.
- •Participation in another clinical study for 3 months prior to inclusion in the study.
- •Other conditions that, according to the physician investigator, prevent the patient from being included in the study.
研究组 & 干预措施
Favipiravir (Areplivir)
Arm 1 (n=106) receives the study drug Areplivir for parenteral administration as follows: Day 1 1600 mg 2 times a day, Day 2-10 800 mg 2 times a day. Administration will be done intravenously by drip infusion for 2 hours. The course of treatment is 10 days. The test drug is administered in hospital setting under supervision of a clinical investigator. The test drug is not handed over to the patient.
干预措施: Favipiravir (Drug)
Standard of care
Arm 2 (n=108) patients receive standard therapy prescribed in accordance with the recommended treatment regimens included in the Interim Guidelines for the prevention, diagnosis and treatment of new coronavirus infection (COVID-19) approved by the Russian Ministry of Health by decision of the investigator and taking into account the availability of drugs at the study site. Might include Favipiravir tab, Remdesivir or other recommended schemes.
Standard therapy is administered in hospital setting. Discharge of patients from a hospital is carried out in accordance with the local practice of the study site in compliance with the current sanitary and epidemiological regime.
干预措施: Favipiravir (Drug)
Standard of care
Arm 2 (n=108) patients receive standard therapy prescribed in accordance with the recommended treatment regimens included in the Interim Guidelines for the prevention, diagnosis and treatment of new coronavirus infection (COVID-19) approved by the Russian Ministry of Health by decision of the investigator and taking into account the availability of drugs at the study site. Might include Favipiravir tab, Remdesivir or other recommended schemes.
Standard therapy is administered in hospital setting. Discharge of patients from a hospital is carried out in accordance with the local practice of the study site in compliance with the current sanitary and epidemiological regime.
干预措施: Remdesivir (Drug)
结局指标
主要结局
Rate of Clinical Status Improvement
时间窗: By Visit 3, approximately 10 days
Rate of clinical status improvement by WHO categorical ordinal scale of clinical status improvement by 2 or more categories by Day 10. WHO Ordinal Scale for Clinical Improvement (WHO-OSCI), 0 - uninfected (There are no clinical and virological signs of infection), 8 - dead, higher scores mean a worse outcome
Time to Clinical Improvement
时间窗: 28 days
Time (in days) to improvement in clinical status by WHO categorical ordinal scale of clinical status improvement
次要结局
- End of Fever on Days of study(14 Days)
- Mortality(28 Days)
- Rate of the Use of Non-invasive Lung Ventilation(28 Days)
- Rate of the Use of Mechanical Ventilation(28 Days)
- Change in the Level of Lung Damage According to CT(14 Days)
- Rate of Transfer to the Intensive Care Unit(28 days)
- Rate of Clinical Status Improvement(14 Days)
- Rate of Viral Elimination(14 days)